Delivery Order VA24217D0012-36C24219F0148
Award Date 12/19/18
Potential Completion Date 9/30/20
Potential Value $8.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Northport, NY 11768, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,808.31 for ACTEMRA ACTPEN 162 MG/0.9 ML (tocilizumab auto-injector pens), a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. The contract was competitively awarded without a set-aside designation and is structured as a firm fixed price delivery order with an ultimate completion date of October 21, 2025. Performance will take place at...
- The National Institute of Dental and Craniofacial Research awarded a $154,073 firm fixed-price purchase order to The Johns Hopkins University for rheumatologist services, with a completion date of November 27, 2026. The contract, which was awarded on November 28, 2025, carries no set-aside designation, indicating open competition. Services will be performed in Bethesda, Maryland. The underlying solicitation was issued as a Special Notice by the National Heart Lung and Blood Institute, a division...
- The Defense Logistics Agency awarded a $2,877.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on August 5, 2025, with an ultimate completion date of August 6, 2025. This non-set-aside contract represents a pharmaceutical delivery to be performed at the contractor's facility in Conshohocken, Pennsylvania. Actemra is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory conditions, making this a...
- The Defense Logistics Agency awarded a delivery order valued at $19,103.04 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis, ankylosing spondylitis, and other autoimmune conditions. The contract was competitively awarded with firm fixed price terms and is scheduled for completion by December 26, 2025. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,151.60 for ACTEMRA 162 mg/0.9 mL syringes on December 17, 2025, with an ultimate completion date of December 18, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a $2,859.85 firm fixed price delivery order to AmerisourceBergen Drug Corp for Actemra ActPen (162 mg/0.9 ml), a biologic immunosuppressant medication used primarily to treat rheumatoid arthritis and other inflammatory conditions. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $3,404.29 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with an ultimate completion date of December 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $9,147.03 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit of use packaging) on May 6, 2025, with an ultimate completion date of May 7, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $20,525.18 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on November 26, 2025, with an ultimate completion date of November 28, 2025. This non-set-aside, firm fixed-price delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of Actemra 400 mg/20 mL vials, a pharmaceutical product used in the treatment of rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, valued at $8,243.54, is scheduled for completion by April 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive...